Top

Published in:

01-06-2010 | Original Paper

TNF-α and its inhibitors in cancer

Authors: Inès Zidi, Souhir Mestiri, Aghleb Bartegi, Nidhal Ben Amor

Published in: Medical Oncology | Issue 2/2010

Abstract

Tumor necrosis factor (TNF)-α is implicated in the same time in apoptosis and in cell proliferation. TNF-α not only acts as pro-inflammatory cytokine conducing to wide spectrum of human diseases including inflammatory diseases, but can also induce tumor development. The molecular mechanisms of TNF-α functions have been intensively investigated. In this review we covered TNF-α, the molecule, its signaling pathway, and its therapeutic functions. We provide a particular insight in its paradoxical role in tumor promotion and in its use as anti-tumor agent. This review considers also the recent findings regarding TNF-α inhibitors, their pharmacokinetics, and their pharmacodynamics. Six TNF-α inhibitors have been considered here: Infliximab, Adalimumab, Golimumab, CDP870, CDP571, Etanercept, and Thalidomide. We discussed the clinical relevance of their functions in treatment of several diseases such as advanced inflammatory rheumatic and bowel disease, with a focus in cancer treatment. Targeting TNF-α by these drugs has many side effects like malignancies development, and the long-term sequels are not very well explored. Their efficacy and their safety were discussed, underscoring the necessity of close patients monitoring and of their caution use.

Carswell E, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–70. doi:10.1073/pnas.72.9.3666.PubMedCrossRef

Feldmann M, et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp. 2004;256:53–69. doi:10.1002/0470856734.ch5.PubMedCrossRef

Locksley R, Killeen N, Lenardo M. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi:10.1016/S0092-8674(01)00237-9.PubMedCrossRef

Black RA, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–33. doi:10.1038/385729a0.PubMedCrossRef

Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392–9. doi:10.1016/S0962-8924(00)89088-1.PubMedCrossRef

Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717–25. doi:10.1056/NEJM199606273342607.PubMedCrossRef

Aggarwal B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–56. doi:10.1038/nri1184.PubMedCrossRef

Tartaglia L, Goeddel D. Two TNF receptors. Immunol Today. 1992;13:151–3. doi:10.1016/0167-5699(92)90116-O.PubMedCrossRef

Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell. 2004;116:491–7. doi:10.1016/S0092-8674(04)00166-7.PubMedCrossRef

10.

Wertz IE, Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev. 2008;19:313–24. doi:10.1016/j.cytogfr.2008.04.014.PubMedCrossRef

11.

Chen G, Goeddel D. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634–5. doi:10.1126/science.1071924.PubMedCrossRef

12.

Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7:758–65. doi:10.1038/ncb0805-758.PubMedCrossRef

13.

Basak S, Hoffmann A. Crosstalk via the NF-kappa B signaling system. Cytokine Growth Factor Rev. 2008;19:187–97. doi:10.1016/j.cytogfr.2008.04.005.PubMedCrossRef

14.

Brenner DA, O’Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of JUN and collagenase genes by tumour necrosis factor-alpha. Nature. 1989;337:661–3. doi:10.1038/337661a0.PubMedCrossRef

15.

Muppidi JR, Tschopp J, Siegl RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461–5. doi:10.1016/j.immuni.2004.10.001.PubMedCrossRef

16.

Kruyt FAE. TRAIL and cancer therapy. Cancer Lett. 2008;263:14–25. doi:10.1016/j.canlet.2008.02.003.PubMedCrossRef

17.

Anderson G, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:314–20. doi:10.1016/j.coph.2004.04.004.PubMedCrossRef

18.

Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14:185–91. doi:10.1016/S1359-6101(03)00022-4.PubMedCrossRef

19.

Kruglov A, et al. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev. 2008;19:231–44. doi:10.1016/j.cytogfr.2008.04.010.PubMedCrossRef

20.

Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure–function relationship(s). Microsc Res Tech. 2000;50:184–95. doi:10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.PubMedCrossRef

21.

Stübgen J-P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281–92. doi:10.1002/mus.20924.PubMedCrossRef

22.

Cope AP, et al. Chronic tumor necrosis factor alter T cells responses by attenuating T cell receptor signalling. J Exp Med. 1997;185:1573–84. doi:10.1084/jem.185.9.1573.PubMedCrossRef

23.

Kodama S, Davis M, Faustman D. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci. 2005;62:1850–62. doi:10.1007/s00018-005-5022-6.PubMedCrossRef

24.

Ban L, et al. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci USA. 2008;105:13644–9. doi:10.1073/pnas.0803429105.PubMedCrossRef

25.

Manusama E, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996;83:551–5. doi:10.1002/bjs.1800830438.PubMedCrossRef

26.

Eggermont A, de Wilt J, ten Hagen T. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429–37. doi:10.1016/S1470-2045(03)01141-0.PubMedCrossRef

27.

Curnis F, Sacchi A, Corti A. Improving the response of tumors to chemotherapy in mice by targeted delivery of picogram doses of tumor necrosis factor-alpha to tumor vessels. J Clin Invest. 2002;110:475–82.PubMed

28.

Folli S, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993;53:829–36. doi:10.1002/ijc.2910530521.PubMedCrossRef

29.

van Horssen R, Ten Hagen T, Eggermont A. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408. doi:10.1634/theoncologist.11-4-397.PubMedCrossRef

30.

ten Hagen T, Seynhaeve A, Eggermont A. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol Rev. 2008;222:299–315. doi:10.1111/j.1600-065X.2008.00619.x.PubMedCrossRef

31.

Fraker DL, Alexander H, Andrich M, Rosenberg S. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479–89.PubMed

32.

Van Horssen R, Ten Hagen TLM, Eggermont AMM. TNF-alpha in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. The Oncologist. 2006;11:397–408. doi:10.1634/theoncologist.11-4-397.PubMedCrossRef

33.

Lejeune F, Rüegg C. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer. 2006;93:E90–100.PubMed

34.

Fajardo L, Kwan H, Kowalski J, Prionas S, Allison A. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992;140:539–44.PubMed

35.

Alexander HJ, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–89.PubMed

36.

Borsi L, et al. Selective targeted delivery of TNF alpha to tumor blood vessels. Blood. 2003;102:4384–92. doi:10.1182/blood-2003-04-1039.PubMedCrossRef

37.

Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann NY Acad Sci. 2004;1028:104–12. doi:10.1196/annals.1322.011.PubMedCrossRef

38.

Senzer N, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22:592–601. doi:10.1200/JCO.2004.01.227.PubMedCrossRef

39.

Chang K, et al. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2008;5:107–11. doi:10.1038/ncpgasthep1033.PubMedCrossRef

40.

Mundt AJ, et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004;10:5747–53. doi:10.1158/1078-0432.CCR-04-0296.PubMedCrossRef

41.

Chung T, et al. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998;5:344–9.PubMed

42.

Staba M, Mauceru H, Kufe D, Hallahan D, Weichselbaum R. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998;5:293–300. doi:10.1038/sj.gt.3300594.PubMedCrossRef

43.

McLoughlin JM, et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor a, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol. 2005;12:825–30. doi:10.1245/ASO.2005.03.023.PubMedCrossRef

44.

Asher AL, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol. 1991;146:3227–34.PubMed

45.

Han SK, Brody SL, Crystal RG. Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA. Am J Respir Cell Mol Biol. 1994;11:270–8.PubMed

46.

Mizuguchi H, et al. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res. 1998;58:5727–30.

47.

Larmonier N, et al. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res. 2007;313:2345–55. doi:10.1016/j.yexcr.2007.03.027.PubMedCrossRef

48.

Tselepsis C, et al. Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071–81. doi:10.1038/sj.onc.1205731.CrossRef

49.

Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor alpha in women with endometriomas and benign and malignant cycstic ovarian tumours. Hum Reprod. 2003;18:1681–5. doi:10.1093/humrep/deg321.PubMedCrossRef

50.

Szlosarek PW, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006;42:745–50. doi:10.1016/j.ejca.2006.01.012.PubMedCrossRef

51.

Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41. doi:10.1016/S1359-6101(01)00020-X.PubMedCrossRef

52.

Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. In: Chernajovsky Y, Nissim A, editors. Therapeutic antibodies. Handbook of experimental pharmacology. 2008, p. 101–129.

53.

Huerta-Yepez SM, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol. 2006;120:297–309. doi:10.1016/j.clim.2006.03.015.PubMedCrossRef

54.

Mocellin S, Riccardo Rossi C, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35–53. doi:10.1016/j.cytogfr.2004.11.001.PubMedCrossRef

55.

Hagemann T, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543–9. doi:10.1093/carcin/bgh146.PubMedCrossRef

56.

Lee HY, et al. A small compound that inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-9 upregulation. Biochem Biophys Res Commun. 2005;336:716–22. doi:10.1016/j.bbrc.2005.08.154.PubMedCrossRef

57.

Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227–39. doi:10.1038/nrc1821.PubMedCrossRef

58.

Nagai S, et al. Glil contributs to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci. 2008;99:1377–84. doi:10.1111/j.1349-7006.2008.00822.x.PubMedCrossRef

59.

Leber TM, Balkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998;78:724–32.PubMed

60.

Szlosarek PW, Balkwill FR. Tumour necrosis factor: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565–73. doi:10.1016/S1470-2045(03)01196-3.PubMedCrossRef

61.

Zidi I, et al. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci. 2006;63:2669–81. doi:10.1007/s00018-006-6341-y.PubMedCrossRef

62.

Jang W, et al. The −238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41–6. doi:10.1016/S0304-3835(01)00438-4.PubMedCrossRef

63.

Hajeer A, et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol. 2000;142:441–5. doi:10.1046/j.1365-2133.2000.03353.x.PubMedCrossRef

64.

Marsh H, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer. 2003;89:1096–101. doi:10.1038/sj.bjc.6601165.PubMedCrossRef

65.

Scallon BJ, Arevalo Moore M, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251–9. doi:10.1006/cyto.1995.0029.PubMedCrossRef

66.

Mitoma H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor-alpha expressing cells comparison among Infliximab, Etanercept, and Adalimumab. Arthritis Rheum. 2008;58:1248–57. doi:10.1002/art.23447.PubMedCrossRef

67.

Daniel PT, Pezzuto A, Dörken B. Humoral immunotherapy and the use of monoclonal antibodies. In: Degos L, LDC, Löwenberg B, editors. Textbook of malignant haematology. Martin Dunitz; 1999, p. 425–46.

68.

Tracey D, Klareskog L, Sasso EH, Salfled Jg, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–79. doi:10.1016/j.pharmthera.2007.10.001.PubMedCrossRef

69.

Duclos M, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol. 2006;33:2433–8.PubMed

70.

Schrumpf Heiberg M, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234–40. doi:10.1002/art.23333.CrossRef

71.

Alonso-Ruiz A, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi:10.1186/1471-2474-9-52.PubMedCrossRef

72.

Carmona L, Gomez-Reino JJS, Group B. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72. doi:10.1186/ar1941.PubMedCrossRef

73.

Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with Etanercept and Infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174. doi:10.1186/ar2084.PubMedCrossRef

74.

Farrell R, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–7. doi:10.1111/j.1572-0241.2000.03366.x.PubMedCrossRef

75.

St Clair E, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43. doi:10.1002/art.20568.PubMedCrossRef

76.

Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681–90. doi:10.1002/art.1780361206.PubMedCrossRef

77.

Wagner C, et al. lnfliximab treatment benefits correlate with pbarmacodynamic parameters in Crohn’s disease patients. Digestion. 1998;59:124–5.

78.

Nakada M, et al. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun. 1998;5:491–503. doi:10.3109/15419069809005606.PubMedCrossRef

79.

Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–33.PubMed

80.

Hommes D, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn’s disease. Haemostasis. 1997;27:269–77.PubMed

81.

Van Dullemen H, et al. Reduction of circulating secretory phospholipase A, levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn’s disease. Relation between tumor necrosis factor and secretory phospholipase A, in healthy humans and active Crohn’s disease. Scand J Gastroenterol. 1998;33:1094–8. doi:10.1080/003655298750026813.PubMedCrossRef

82.

Flamant M, Bourreille A. Biothérapies et MICI: anti-TNF et nouvelles cibles thérapeutiques Biologic therapies in inflammatory bowel disease. Rev Med Interne. 2007;28:852–61. doi:10.1016/j.revmed.2007.06.008.PubMedCrossRef

83.

Baert F, et al. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–8. doi:10.1056/NEJMoa020888.PubMedCrossRef

84.

Weinblatt M, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45. doi:10.1002/art.10697.PubMedCrossRef

85.

Van der Heijde D, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double blind, placebocontrolled trial. Arthritis Rheum. 2006;54:2136–46. doi:10.1002/art.21913.PubMedCrossRef

86.

Mease P, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89. doi:10.1002/art.21306.PubMedCrossRef

87.

Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:349–64. doi:10.1016/j.rdc.2004.02.004.PubMedCrossRef

88.

Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the Macaque immune system. Am J Reprod Immunol. 2007;58:138–49. doi:10.1111/j.1600-0897.2007.00499.x.PubMedCrossRef

89.

Kay J, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964–75. doi:10.1002/art.23383.PubMedCrossRef

90.

Zhou H, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383–96. doi:10.1177/0091270006298188.PubMedCrossRef

91.

Inman RD, et al. Efficacy and safety of Golimumab in patients with ankylosing spondylitis results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–12. doi:10.1002/art.23969.PubMedCrossRef

92.

Hutas G. Golimumab, a fully human monoclonal antibody against TNF-alpha. Curr Opin Mol Ther. 2008;10:393–406.PubMed

93.

Sandborn WJ, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–38. doi:10.1056/NEJMoa067594.PubMedCrossRef

94.

Schreiber S, et al. Maintenance therapy with Certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–50. doi:10.1056/NEJMoa062897.PubMedCrossRef

95.

Winter G, Harris W. Humanized antibodies. Immunol Today. 1993;14:243–6. doi:10.1016/0167-5699(93)90039-N.PubMedCrossRef

96.

Stack WA, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor in Crohn’s disease. Lancet. 1997;349:521–4. doi:10.1016/S0140-6736(97)80083-9.PubMedCrossRef

97.

Sandborn WJ, et al. An open-label study of the human anti-TNF monoclonal antibody Adalimumab in subjects with prior loss of response or intolerance to Infliximab for Crohn’s disease. Am J Gastroenterol. 2004;99:1984–9. doi:10.1111/j.1572-0241.2004.40462.x.PubMedCrossRef

98.

Feagan BG, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:617–28. doi:10.1111/j.1365-2036.2006.02791.x.PubMedCrossRef

99.

Sandborn W, et al. Etanercept for active Crohn’s disease: a randomized, double blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–94. doi:10.1053/gast.2001.28674.PubMedCrossRef

100.

Nanda S, Bathon J. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004;5:1175–86. doi:10.1517/14656566.5.5.1175.PubMedCrossRef

101.

Speirs A. Thalidomide and congenital abnormalities. Lancet. 1962;1:303–5. doi:10.1016/S0140-6736(62)91248-5.PubMedCrossRef

102.

Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med. 2002;6:160–74. doi:10.1111/j.1582-4934.2002.tb00184.x.PubMedCrossRef

103.

Combe B. Le thalidomide: vers de nouvelles indications ? Rev Rhum. 2001;68:951–7. doi:10.1016/S1169-8330(01)00208-3.CrossRef

104.

Moreira AL, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675–80. doi:10.1084/jem.177.6.1675.PubMedCrossRef

105.

Niwayama S, Turk BE, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem. 1996;39:3044–5. doi:10.1021/jm960284r.PubMedCrossRef

106.

Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of Thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380–6.PubMed

107.

D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5. doi:10.1073/pnas.91.9.4082.PubMedCrossRef

108.

Keifer JA, Guttridge DC, Ashburner BP, Baldwin ASJ. Inhibition of NF-kappa B activity by thalidomide through suppression of Ikappa B kinase activity. J Biol Chem. 2001;276:22382–7. doi:10.1074/jbc.M100938200.PubMedCrossRef

109.

Teo Steven K. Properties of Thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005;7:E14–9. doi:10.1208/aapsj070103.PubMedCrossRef

110.

Haslett P, Corral L, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–92. doi:10.1084/jem.187.11.1885.PubMedCrossRef

111.

Laber DA, et al. A phase I study of Thalidomide, Capecitabine and Temozolomide in advanced cancer. Cancer Biol Ther. 2007;6:840–5.PubMed

112.

Joshua DE. Multiple myeloma: the present and the future. Med J Aust. 2005;183:344.PubMed

113.

Alessandri C, et al. Autoantibody production in anti-TNF-alpha-treated patients. Ann NY Acad Sci. 2007;1110:319–29. doi:10.1196/annals.1423.034.PubMedCrossRef

114.

Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601–11. doi:10.1016/S1473-3099(08)70227-5.PubMedCrossRef

115.

Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183:205–8.PubMed

116.

Ozorio G, et al. Autoimmune hepatitis following Infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524–6.PubMed

117.

Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioglu E. Development of Crohn’s disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis. 2008;10:953–4.PubMed

118.

Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–40. doi:10.1161/01.CIR.0000077913.60364.D2.PubMedCrossRef

119.

Keystone EC. Advances in targeted therapy: safety of biological agents. Ann Rheum Dis. 2003;62:ii34–6. doi:10.1136/ard.62.suppl_2.ii34.PubMedCrossRef

120.

Askling J, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414–20. doi:10.1136/ard.2004.033241.PubMedCrossRef

121.

Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85. doi:10.1001/jama.295.19.2275.PubMedCrossRef

122.

Okada S, Siegel J. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA. 2006;296:2201–2. doi:10.1001/jama.296.18.2201-b.PubMedCrossRef

123.

Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with Infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7. doi:10.1097/MPG.0b013e31802f6424.PubMedCrossRef

124.

Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma. 2007;48:1410–3. doi:10.1080/10428190701345433.PubMedCrossRef

125.

Drini M, Prichard PJ, Brown GJ, Macrae FA. Hepatosplenic T-cell lymphoma following Infliximab therapy for Crohn’s disease. Med J Aust. 2008;189:464–5.PubMed

126.

Geborek P, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703. doi:10.1136/ard.2004.030528.PubMedCrossRef

127.

Nair B, Raval G, Mehta P. TNF-alpha inhibitor Etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007;82:1022–4. doi:10.1002/ajh.20926.PubMedCrossRef

128.

Bakland G, Nossent H. Acute myelogenous leukaemia following Etanercept therapy. Rheumatology. 2003;42:900–1. doi:10.1093/rheumatology/keg128.PubMedCrossRef

129.

Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MMT. Tumor necrosis factor antagonist therapy and lymphoma development twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151–8. doi:10.1002/art.10679.PubMedCrossRef

130.

Stone JH, et al. Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept trial. Arthritis Rheum. 2006;54:1608–18. doi:10.1002/art.21869.PubMedCrossRef

131.

Humira™ (Adalimumab), DN0735V7 CR22-05126. December 20, 2002:16p.

132.

Solomon DH. The comparative safety and effectiveness of TNF-alpha antagonists. J Manag Care Pharm. 2007;13:S7–18.PubMed

133.

Curnis F, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185–90. doi:10.1038/81183.PubMedCrossRef

134.

Kianmanesh A, et al. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naïve dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther. 2001;12:2035–49. doi:10.1089/10430340152677395.PubMedCrossRef

135.

Manusama ER, et al. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam Preclinical-Clinical Program. Semin Surg Oncol. 1998;14:232–7. doi:10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9.PubMedCrossRef

136.

Lewis JD. Anti-TNF antibodies for Crohn’s disease- In pursuit of the perfect clinical trial. N Engl J Med. 2007;357:296–8. doi:10.1056/NEJMe078111.PubMedCrossRef

137.

Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, Omalizumab, Infliximab, Etanercept, Adalimumab, Efalizumab, and Alefacept (Part 2 of 2). J Am Acad Dermatol. 2007;56:e55–79. doi:10.1016/j.jaad.2006.07.019.PubMedCrossRef

138.

Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor blocking agents Adalimumab, Etanercept, and Infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2003;62(Suppl II):ii13–6. doi:10.1136/ard.62.suppl_2.ii13.PubMed

139.

Doan QV, Chiou C-F, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (Adalimumab, Etanercept, and Infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555–69.PubMed

140.

Chen Y-F, et al. A systematic review of the effectiveness of Adalimumab, Etanercept and Infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii–iv, xi–xiii, 1–229.

141.

Thiéfin G, Morelet A, Heurgué A, Diebold M-D, Eschard J-P. Infliximab-induced hepatitis: absence of cross-toxicity with Etanercept. Joint Bone Spine. 2008;75:737–9. doi:10.1016/j.jbspin.2007.12.009.PubMedCrossRef

142.

Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents: A guide for GPs. Aust Fam Physician. 2007;36:1035–8.PubMed

143.

Fonseca JE, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors—March 2008 update. Acta Reumatol Port. 2008;33:77–85.PubMed

144.

Theis VS, Rhodes JM. Minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.PubMedCrossRef

145.

Gupta A, Street AC, Macrae FA. Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease. MJA. 2008;188:168–70.PubMed

146.

Tayal V, Kalra B. Cytokines and anti-cytokines as therapeutics—an update. Eur J Pharmacol. 2008;579:1–12. doi:10.1016/j.ejphar.2007.10.049.PubMedCrossRef

147.

Schreiber S, et al. A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–18. doi:10.1053/j.gastro.2005.06.064.PubMedCrossRef

Title: TNF-α and its inhibitors in cancer
Authors: Inès Zidi
Souhir Mestiri
Aghleb Bartegi
Nidhal Ben Amor
Publication date: 01-06-2010
Publisher: Springer US
Published in: Medical Oncology / Issue 2/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-009-9190-3

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis

Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience

Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response

Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis

Proliferation inhibition effect of docetaxel combined with cisplatin on osteosarcoma cells

Diffuse large B-cell lymphoma: experience from a tertiary care center in north India

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage